Advertisement


Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Opportunities to Optimize Cancer Policies Panel Discussion

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Advertisement

Advertisement




Advertisement